
Somatostatin Receptors and Circulating Biomarkers in NETs
Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, and Jonathan R. Strosberg, MD, of Moffitt Cancer Center, discuss the biomarkers that guide neuroendocrine tumor (NET) care with moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University.
Episodes in this series

Simron Singh, MD, MPH, of Sunnybrook Odette Cancer Centre, and Jonathan R. Strosberg, MD, of Moffitt Cancer Center, discuss the biomarkers that guide neuroendocrine tumor (NET) care with moderator Daniel M. Halperin, MD, of Winship Cancer Institute of Emory University. Singh explains why somatostatin receptor expression is such a valuable target: it is present on most well-differentiated NETs, it is stable over time, it improves staging, and it serves as a therapeutic target for somatostatin analogs and radioligand therapy, making NETs a pioneer in that field. Strosberg separates hormones, such as serotonin and 5-hydroxyindoleacetic acid in carcinoid syndrome or specific hormones in functional pancreatic NETs, from nonspecific markers such as chromogranin, pancreastatin, and neuron-specific enolase. He finds the nonspecific markers less useful than once thought because they fluctuate and are affected by proton pump inhibitors. Newer molecular tests and circulating tumor DNA remain under study, so scans still carry more weight than circulating biomarkers.
Related to this article








